Ultimele actualizari :
19/11/2024
Citostatic   Bortezomib  
Injectabil
Stabilitatea in solutie Stabilitatea in amestec Factorii care influenteaza stabilitatea Compatibilitate Microunde Bibliografie pdf
   Formula chimica  

Denumirea comerciala   Denumirea comerciala     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Bemoncaz Mexic
Bicavan Chilli
Biemib Turcia
Bomib Mexic
Borater Argentina
Borcade Turcia
Bormib Argentina
Bortezomib noua Zeelandă
Bortezun Ecuador
Bortrac Ecuador, Peru
Bortzo Peru
Botemib Chilli, Ecuador, Peru
Bozix Chilli, Peru
Bozob Argentina, Ecuador, Peru
Bromadene Argentina
Egybort India
Elomaziv Mexic
Gysatri Argentina
Miasoma Argentina
Mibor Peru
Multizom Argentina
Rebtik Chilli
Velcade Arabia Saudita, Argentina, Australia, Austria, Belgia, Canada, Chilli, Columbia, Danemarca, Egipt, Elvetia, Emiratele Arabe Unite, Finlanda, Franta, Germania, Grecia, Irlanda, Islanda, Italia, Japonia, Luxemburg, Malaezia, Marea Britanie, Mexic, Norvegia, noua Zeelandă, Olanda, Polonia, Portugalia, Romania, Spania, SUA, Suedia, Turcia, Ungaria, Venezuela
Velcord Peru
Vortemyel Romania
Zefra Argentina
Zegomib Romania
Zuricade Mexic
Bibliografie   Injectabil   Bibliografie : Bortezomib  
tip publicare
1911 Laborator Bortezomib (Velcade®) - Summary of Product Characteristics
Janssen-Cilag Ltd 2016
2010 ziar André P, Cisternino S, Chiadmi F, Toledano A, Schlatter J, Fain O, Fontan JE.
Stability of bortezomib 1 mg/ml solution in plastic syringe and glass vial.
Ann Pharmacotherapy 2005 ; 39: 1462-1466.
2011 ziar Friess D, Nguyen HC, Lipp HP.
HPLC-stabilitätuntersuchungen zu rekonstituierten Bortezomib-Lösungen.
Krankenhauspharmazie 2005 ; 26, 6: 206-210.
2232 ziar Walker SE, Milliken D, Law S.
Stability of Bortezomib Reconstituted with 0.9% Sodium Chloride at 4°C and Room Temperature (23°C)
Can J Hosp Pharm 2008 ; 61, 1: 14-20.
3190 ziar Bolognese A, Esposito A, Manfra M, Catalano L, Petruzziello F, Martorelli MC, Pagliuca R, Mazzarelli V, Ottiero M, Scalfaro M,
An NMR Study of the Bortezomib Degradation under Clinical Use Conditions.
Advance in Haematology 2009 Article ID 704928, 5 page
3240 poster Perissutti M, Vigneron J, Zenier H, May I, Demoré B.
Etude de la stabilité d'une solution de bortézomib à 1 mg/mL conditionnée en seringue de polypropylène.
Congrès SFPO 2011
3337 ziar Carati D, Masini C, Minguzzi M, Petocchi B, Romanazzi C, Rondoni C, Sangiorgi E, Sferra S, Simonetta S, Stancari A, Locchi F, Z
Stability of bortezomib reconstituted under clinical use conditions in original vials and polypropylene syringes at 4 °C and room temperature.
EJHP 2012 ; 19: 428-431.
3349 ziar Bosch-Ojeda C, Sanchez-Rojas M.F, Espinosa-Bosch M.
Chemical stability of bortezomib solutions in original manufacturer vials.
Int J Pharm Bio Sci 2012 ; 2, 3: 344-350.
3418 ziar Berruezo garcia J, Espinosa Bosch M, Sanchez Rojas F, Bosch Ojeda C
Chemical stability of bortezomib solutions in original manufacturer vial at room temperature and in syringe at 4°C.
Int J Pharm Bio Sci 2013 ; 3, 1: 449-458.
3447 poster Giovanelli M, Vigneron J, May I, Nicolas A.
Etude de la stabilité d’une solution de bortézomib à 2,5 mg/mL par chromatographie liquide à haute performance couplée à un détecteur à barrettes de diodes et à un détecteur évaporatif à diffusion de lumière.
SFPO Congress, Mandelieu, France 2013
3537 ziar Lipp HP, Gfrörer W, Riedmüller S.
Bortezomib zur subkutanen Applikation.
Krankenhauspharmazie 2013 ; 34,11: 500-505.
3688 ziar Walker S.E, Charbonneau L.F, Law S.
Stability of bortezomib 2.5 mg/mL in vials and syringes stored at 4°C and room temperature (23°C).
Can J Hosp Pharm 2014 ; 67, 2: 102-107
4137 ziar Patel T, Sewell G.
Short Report : Extended Stability Studies on Bortezomib Injection and Infusions of Cisplatin and Pemetrexed (all Accord Healthcare).
Newsletter Stabilis 2018 41;2-6
4485 ziar Law S, Charbonneau L, Iazetta J, Perks W, Ma N, Walker S.E.
Stability of Generic Formulations of Bortezomib 1.0 and 2.5 mg/mL in Vials and Syringes Stored 4°C and Room Temperature (23°C)
Can J Hosp Pharm 2021 ;74;1:57-69

  Mentions Légales